| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| September 26th, 2005 | 21 | Yes |
Popular Name: Furosemide Furosemide
Find On: PubMed — Wikipedia — Google
CAS Numbers: 54-31-9 , [41733-55-5] , [54-31-9]
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
4-Chloro-2-[(furan-2-ylmethyl)-amino]-5-sulfamoyl-benzoic acid
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
4-Chloro-2-{[(fur-2-yl)methyl]amino}-5-sulphamoylbenzoic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
4-Chloro-N-Furfuryl-5-SulfamoylanthranilicAcid
41733-55-5 (mono-hydrochloride salt)
5-(aminosulfonyl)-4-chloro-2-[(2-furylmethyl)amino]benzoic acid
5-18-09-00555 (Beilstein Handbook Reference)
54-31-9; CPD000058202; FUROSEMIDE; SAM002264614
54-31-9; D00331; Frusemide; Furosemide (JP16/USP/INN); Lasix (TN)
54-31-9; Furosemide; Prestwick_752
Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl-
benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]-
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]
CPD000058202; Furosemide; SAM002264614
D08001; Furosemide diethanolamine salt; Furosemide diolamine; Nuriban (TN)
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 1.77 | 1.53 | -50.99 | 3 | 7 | -1 | 125 | 329.741 | 5 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| ALOGPS_SOLUBILITY | 1.18e-01 g/l | DrugBank-approved |
| MP | 205 | TCI |
| Purity | 97% | APIChem |
| biological_use | Antihypertensive | IBScreen Bioactives |
| Indications | antihypertensive, edema, diuretic | KeyOrganics Bioactives |
| biological_use | Antihypertensive | IBScreen Bioactives |
| UniProt Database Links | CLCKA_RAT; INDY1_DROME; S12A4_RABIT; S12A4_RAT; S12A5_HUMAN; S12A5_RAT; S12A6_HUMAN; S12A7_HUMAN; S226A_XENLA; S226B_XENLA; S22A6_BOVIN; S22A6_DANRE; S22A6_HUMAN; S22A6_MACFA; S22A6_MOUSE; S22A6_PIG; S22A6_PONAB; S22A6_PSEAM; S22A6_RABIT; S22A6_RAT | ChEBI |
| biological_use | Diuretic | IBScreen Bioactives |
| Therapy | diuretic, antihypertensive | SMDC Iconix |
| Indications | edema, hypertension | KeyOrganics Bioactives |
| Patent Database Links | EP0795327; EP1428531; EP1457490; EP1479666; EP1533292; EP1595540; EP1669074; EP1669345; EP1717226; EP1746099; EP1829858; EP1844774; EP1862181; EP1884513; EP1889847; EP1891943; EP1932529; EP1972336; GB2264710; US2002115655; US2004147575; US2005009870; US20 | ChEBI |
| H phrase | H360: May damage fertility or the unborn child | Acros Organics |
| mechanism | Inhibitor of carbonic anhydrase, | IBScreen Bioactives |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : F-4167 | NIH Clinical Collection via PubChem |
| Target | Others | Selleck Chemicals |
| P phrase | P201: Obtain special instructions before use; P202: Do not handle until all safety precautions have been read and understood; P281: Use personal protective equipment as required; P308 + P313: IF exposed or concerned: Get medical advice/attention | Acros Organics |
| R phrase | R61: May cause harm to the unborn child. | Acros Organics |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: F-4167 | NIH Clinical Collection via PubChem |
| Target | Sodium Channel | Selleck Chemicals |
| mechanism | subtype-specific blocker of GABA-A receptors | IBScreen Bioactives |
| Hazard | T: Toxic | Acros Organics |
| biological_use | Used for treatment of cirrhotic patients with ascites. | IBScreen Bioactives |
| biological_use | Used in conjunction with Spironolactone HJR81-N for prophylaxis of hypokalaemia and hepatic encephalopathy or in treatment of hyperaldosteronism | IBScreen Bioactives |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| CAH1-1-E | Carbonic Anhydrase I (cluster #1 Of 12), Eukaryotic | Eukaryotes | 62 | 0.48 | Binding ≤ 10μM |
| CAH12-1-E | Carbonic Anhydrase XII (cluster #1 Of 9), Eukaryotic | Eukaryotes | 261 | 0.44 | Binding ≤ 10μM |
| CAH13-1-E | Carbonic Anhydrase XIII (cluster #1 Of 7), Eukaryotic | Eukaryotes | 550 | 0.42 | Binding ≤ 10μM |
| CAH14-1-E | Carbonic Anhydrase XIV (cluster #1 Of 8), Eukaryotic | Eukaryotes | 52 | 0.49 | Binding ≤ 10μM |
| CAH2-1-E | Carbonic Anhydrase II (cluster #1 Of 15), Eukaryotic | Eukaryotes | 65 | 0.48 | Binding ≤ 10μM |
| CAH4-1-E | Carbonic Anhydrase IV (cluster #1 Of 16), Eukaryotic | Eukaryotes | 564 | 0.42 | Binding ≤ 10μM |
| CAH5A-1-E | Carbonic Anhydrase VA (cluster #1 Of 10), Eukaryotic | Eukaryotes | 499 | 0.42 | Binding ≤ 10μM |
| CAH5B-1-E | Carbonic Anhydrase VB (cluster #1 Of 9), Eukaryotic | Eukaryotes | 322 | 0.43 | Binding ≤ 10μM |
| CAH6-7-E | Carbonic Anhydrase VI (cluster #7 Of 8), Eukaryotic | Eukaryotes | 245 | 0.44 | Binding ≤ 10μM |
| CAH7-1-E | Carbonic Anhydrase VII (cluster #1 Of 8), Eukaryotic | Eukaryotes | 513 | 0.42 | Binding ≤ 10μM |
| CAH9-1-E | Carbonic Anhydrase IX (cluster #1 Of 11), Eukaryotic | Eukaryotes | 420 | 0.43 | Binding ≤ 10μM |
| DHI1-1-E | 11-beta-hydroxysteroid Dehydrogenase 1 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 3760 | 0.36 | Binding ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| CAH1_HUMAN | P00915 | Carbonic Anhydrase I, Human | 62 | 0.48 | Binding ≤ 1μM |
| CAH2_HUMAN | P00918 | Carbonic Anhydrase II, Human | 65 | 0.48 | Binding ≤ 1μM |
| CAH4_HUMAN | P22748 | Carbonic Anhydrase IV, Human | 564 | 0.42 | Binding ≤ 1μM |
| CAH9_HUMAN | Q16790 | Carbonic Anhydrase IX, Human | 420 | 0.43 | Binding ≤ 1μM |
| CAH5A_HUMAN | P35218 | Carbonic Anhydrase VA, Human | 499 | 0.42 | Binding ≤ 1μM |
| CAH5B_HUMAN | Q9Y2D0 | Carbonic Anhydrase VB, Human | 322 | 0.43 | Binding ≤ 1μM |
| CAH6_HUMAN | P23280 | Carbonic Anhydrase VI, Human | 245 | 0.44 | Binding ≤ 1μM |
| CAH7_HUMAN | P43166 | Carbonic Anhydrase VII, Human | 513 | 0.42 | Binding ≤ 1μM |
| CAH12_HUMAN | O43570 | Carbonic Anhydrase XII, Human | 261 | 0.44 | Binding ≤ 1μM |
| CAH13_MOUSE | Q9D6N1 | Carbonic Anhydrase XIII, Mouse | 550 | 0.42 | Binding ≤ 1μM |
| CAH14_HUMAN | Q9ULX7 | Carbonic Anhydrase XIV, Human | 52 | 0.49 | Binding ≤ 1μM |
| DHI1_MOUSE | P50172 | 11-beta-hydroxysteroid Dehydrogenase 1, Mouse | 3760 | 0.36 | Binding ≤ 10μM |
| DHI1_HUMAN | P28845 | 11-beta-hydroxysteroid Dehydrogenase 1, Human | 3760 | 0.36 | Binding ≤ 10μM |
| CAH1_HUMAN | P00915 | Carbonic Anhydrase I, Human | 62 | 0.48 | Binding ≤ 10μM |
| CAH2_HUMAN | P00918 | Carbonic Anhydrase II, Human | 65 | 0.48 | Binding ≤ 10μM |
| CAH4_HUMAN | P22748 | Carbonic Anhydrase IV, Human | 564 | 0.42 | Binding ≤ 10μM |
| CAH9_HUMAN | Q16790 | Carbonic Anhydrase IX, Human | 420 | 0.43 | Binding ≤ 10μM |
| CAH5A_HUMAN | P35218 | Carbonic Anhydrase VA, Human | 499 | 0.42 | Binding ≤ 10μM |
| CAH5B_HUMAN | Q9Y2D0 | Carbonic Anhydrase VB, Human | 322 | 0.43 | Binding ≤ 10μM |
| CAH6_HUMAN | P23280 | Carbonic Anhydrase VI, Human | 245 | 0.44 | Binding ≤ 10μM |
| CAH7_HUMAN | P43166 | Carbonic Anhydrase VII, Human | 513 | 0.42 | Binding ≤ 10μM |
| CAH12_HUMAN | O43570 | Carbonic Anhydrase XII, Human | 261 | 0.44 | Binding ≤ 10μM |
| CAH13_MOUSE | Q9D6N1 | Carbonic Anhydrase XIII, Mouse | 550 | 0.42 | Binding ≤ 10μM |
| CAH14_HUMAN | Q9ULX7 | Carbonic Anhydrase XIV, Human | 52 | 0.49 | Binding ≤ 10μM |
| Description | Species |
|---|---|
| Erythrocytes take up carbon dioxide and release oxygen | |
| Erythrocytes take up oxygen and release carbon dioxide | |
| Glucocorticoid biosynthesis | |
| Regulation of gene expression by Hypoxia-inducible Factor | |
| Reversible hydration of carbon dioxide |
